Therapeutic compositions, devices and protocols for the treatment of
keloids and other abnormal scars with improved appearance and a much
lower recurrence rate. A therapeutic drug delivery device comprises an
injectable mixture of a fibroblast inhibitor such as corticosteroid and a
slow release carrier such as milled gel sponge dispersed in a fluid
medium such as biological saline. The composition can be injected
perilesionally in the dermis following excision of the keolid or other
scar tissue, to circumscribe the wound. The infiltration of the mixture
around the wound can provide a slow release of the fibroblast inhibitor
for an extended period of time until normal wound closure can dominate
and keloid or abnormal scar recurrence is inhibited.